AMGEN Inc
NASDAQ: AMGN
$278.76
-$2.58 (-0.9%)
Closing Price on November 18, 2024
AMGN Articles
Amgen Inc. (NASDAQ: AMGN) reported its fourth-quarter financial results after the markets closed on Thursday. This biotech giant posted $2.89 in earnings per share (EPS) and $5.97 billion in revenue,...
Published:
Last Updated:
Although this earnings season has been relatively positive, the Dow has stepped away from its 20,000 mark, and it seems the animal spirits powering this rally might not be as positive as they once...
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday include Amgen, Apple, Corning, Mobileye, Under Armour and Electronic Arts.
Published:
Last Updated:
As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears have to say about this rally.
Published:
Last Updated:
A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks to buy that have a large enough market cap to provide some safety.
Published:
Last Updated:
As we have approached Trump’s inauguration, the health care sector in general has rallied. Now it’s time to see what the bears have to say about this rally.
Published:
Last Updated:
2017 could be different for the health care sector. It is very possible that this new administration could lead to more positive trials, FDA approvals, and mergers and acquisitions.
Published:
Last Updated:
The December 15 short interest data have been compared with the previous report, and short interest was down in most of the selected biotech stocks.
Published:
Last Updated:
Tthe top analyst upgrades, downgrades and initiations seen on Tuesday morning include Amgen, American Express, American Water Works, Celgene and Square.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Amgen, Coca-Cola, IBM, Procter & Gamble, Viacom, SeaWorld and NovoCure.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous report, and short interest was mixed in the selected biotech stocks.
Published:
Last Updated:
The November 15 short interest data have been compared with the previous report, and short interest increased in most of the selected biotech stocks.
Published:
Last Updated:
With the Republicans now set to control both Congress and the White House, many on Wall Street feel that there could be far less scrutiny on drug pricing.
Published:
Last Updated:
Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can breathe a little easier knowing that the pressure is off, if for just now at...
Published:
Last Updated:
The broad markets are holding steady near their double bottom set this summer. However, over the course of the past week this has been tested.
Published:
Last Updated: